- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Novartis in crisis management mode; Elanco buys Bayer’s animal health business for US$ 7.6 billion | 24 August, 2019
The Swiss drugmaker is now trying to restrict the damage it has caused to the company’s image, with CEO Vas Narasimhan even admitting that the furor could have been handled better.
The USFDA approved five drugs last week, including Celgene’s myelofibrosis drug Inrebic, Roche’s cancer drug Rozlytrek and AbbVie’s rheumatoid arthritis drug Rinvoq.
In the US, the House Committee on Oversight and Reform sent letters to Heritage Pharma, Mylan and Teva and renewed its 2014 request for furbishing details on the price rise of generics.
Elanco bought Bayer’s animal health unit for US$ 7.6 billion.
AstraZeneca diabetes drug Farxiga showed promise in heart failure.
And the FDA said it would deactivate outdated drug listing records in its database.
(Source: Pharmacompass)